RTC
MRNA icon

Riverview Trust Company’s Moderna MRNA Stock Holding History

Riverview Trust Company’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-486
Closed -$20.2K – 745
2024
Q4 		$20.2K Buy
+486
New +$23.2K 0.02% 460
2024
Q3 		– Sell
-173
Closed -$20.5K – 843
2024
Q2 		$20.5K Hold
173
– – 0.02% 418
2024
Q1 		$18.4K Buy
+173
New +$17.4K 0.01% 515
2023
Q4 		– Sell
-272
Closed -$28.1K – 437
2023
Q3 		$28.1K Buy
272
+65
+31% +$7.25K 0.02% 315
2023
Q2 		$25.2K Buy
207
+46
+29% +$6.14K 0.02% 304
2023
Q1 		$24.7K Buy
161
+11
+7% +$1.81K 0.02% 302
2022
Q4 		$27K Sell
150
-89
-37% -$14.6K 0.03% 296
2022
Q3 		$28K Buy
239
+40
+20% +$6.07K 0.03% 296
2022
Q2 		$28K Sell
199
-36
-15% -$5.15K 0.02% 303
2022
Q1 		$40K Buy
+235
New +$39.6K 0.03% 248

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Riverview Trust Company's MRNA Position: Q1 2025 in Review

Riverview Trust Company sold out of Moderna (MRNA) in Q1 2025, closing a stake of 486 shares — an estimated $20.2K sold.

Riverview Trust Company first reported a position in MRNA in Q1 2022 and held it in 10 quarters. The position peaked at $40K in Q1 2022. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • Riverview Trust Company reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • Riverview Trust Company sold 486 Moderna shares in Q1 2025, an estimated $20.2K.
  • Riverview Trust Company first reported a position in Moderna in Q1 2022 and held it in 10 quarters.
  • Riverview Trust Company's Moderna position peaked at $40K in Q1 2022.
  • 693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Riverview Trust Company's 13F filing for Q1 2025, filed 11 Apr 2025.